The Mississippi Delta Health Collaborative Medication Therapy Management Model: Public Health and Pharmacy Working Together to Improve Population Health in the Mississippi Delta

Leigh Ann Ross, PharmD; Lauren S. Bloodworth, PharmD; Meagan A. Brown, PharmD; Scott S. Malinowski, PharmD; Rebecca Crane, PharmD; Victor Sutton, PhD; Masoumeh Karimi, PhD, MPH; A. Cassandra Dove Brown; Thomas Dobbs, MD, MPH; Lisle Hites, MS, MEd, PhD

Abstract

Introduction
The Mississippi Delta has high rates of chronic disease and is known for its poor health outcomes and health disparities. The University of Mississippi School of Pharmacy (UMSOP) and the Mississippi State Department of Health partnered in 2009 through the Mississippi Delta Health Collaborative to reduce health disparities and improve clinical outcomes by expanding the UMSOP’s evidence-based medication therapy management (MTM) initiative, focused in Mississippi’s 18-county Delta region, to federally qualified health centers (FQHCs) in 4 of those counties.

Methods
Between January 2009 and August 2018, the MTM initiative targeted FQHC patients aged 18 years or older with a diagnosis of diabetes, hypertension, and/or dyslipidemia. Pharmacists initially met face-to-face with patients to review all medications, provide education about chronic diseases, identify and resolve drug therapy problems, and take appropriate actions to help improve the effectiveness of medication therapies. Clinical parameters evaluated were systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and hemoglobin A1c (HbA1c).

Results
The analysis included 335 patients with hypertension (n = 287), dyslipidemia (n = 131), and/or diabetes (n = 331). Significant mean reductions occurred in the following metrics: SBP (7.1 mm
were not readily available.

CVD and health disparities were prevalent and MTM services
health centers (FQHCs) in 4 Mississippi Delta counties where
an initiative from community pharmacies into federally qualified
State Department of Health partnered in 2009 to expand the MTM
comes for patients in this region, the UMSOP and the Mississippi
Health Collaborative (MDHC) to implement evidence-based
strategies in the Mississippi Delta for CVD prevention and man-
agement. With this shared goal of improving cardiovascular out-
comes, as well as improving measures of patient and provider sat-
isfaction (7–13). Ensuring appropriate medication use can im-
prove CVD clinical outcomes, reduce mortality rates, and de-
crease health care costs (14).

To address the detrimental effect of CVD in this region, the Uni-
versity of Mississippi School of Pharmacy (UMSOP) started a
community-based research program in 2008 that implemented
pharmacist-delivered MTM services. That same year, the Missis-
ippi State Department of Health, with funding from the Centers
for Disease Control and Prevention, created the Mississippi Delta
Health Collaborative (MDHC) to implement evidence-based
strategies in the Mississippi Delta for CVD prevention and man-
agement. With this shared goal of improving cardiovascular out-
comes for patients in this region, the UMSOP and the Mississippi
State Department of Health partnered in 2009 to expand the MTM
initiative from community pharmacies into federally qualified
health centers (FQHCs) in 4 Mississippi Delta counties where
CVD and health disparities were prevalent and MTM services
were not readily available.

Methods

The UMSOP implemented a program to integrate pharmacists as
members of health care teams at FQHCs and provide MTM ser-
ices focused on CVD risk reduction in underserved patients in
rural Mississippi. MTM services were provided and evaluated in 4
FQHCs in the Mississippi Delta: Aaron E. Henry Community
Health Services Center in Batesville (Panola County) and Clarks-
dale (Coahoma County), G.A. Carmichael Family Health Center
in Yazoo City (Yazoo County), and Vicksburg-Warren Family
Health Care Clinic (Warren County). Between January 2009 and
August 2018, the MTM initiative enrolled FQHC patients aged 18
years or older with a diagnosis of diabetes, hypertension, and/or
dyslipidemia. Patients were included in the outcomes analysis if
they had at least 1 follow-up visit within 12 months after enroll-
ment. This project was approved by the University of Mississippi
institutional review board.

For the clinical outcomes analysis portion of this partnership eval-
uation, we focused on the most recent 12-month period funding
cycle. This period was chosen because it was most representative
of the culmination of our partnership efforts and clinical practice
guidelines.

Intervention. Participating patients were current FQHC patients
referred to the program by practitioners of participating clinics in an
attempt to improve outcomes of existing chronic diseases they
were being treated for, patients newly diagnosed with 1 of the
identified chronic diseases, or patients at risk for CVD. Services
provided were developed based on the MTM Core Elements Ser-
vice Model, which includes medication therapy review, personal
medication record, medication-related action plan, intervention or
referral, and documentation and follow-up (15). Upon consent and
enrollment, clinical pharmacists set appointments to see patients
for an initial encounter. Before the face-to-face encounter, the
pharmacists reviewed patients’ records to determine what mea-
ures were needed to help patients achieve their desired health
goals.

Initial pharmacist MTM visit. During the 60-minute initial visit,
the pharmacist performed any number of the following activities
depending on the patient’s needs, including but not limited to the
following:

• Conducting a comprehensive medication review and a medica-
tion reconciliation
• Identifying and resolving potential and actual drug therapy problems
• Assessing clinical parameters, including systolic blood pressure (SBP), dia-
estolic blood pressure (DBP), total cholesterol, low-density lipoprotein (LDL)
cholesterol, triglycerides, and hemoglobin A\(_1c\) (HbA\(_1c\)) to determine needed

Hg), DBP (6.3 mm Hg), LDL cholesterol (24.9 mg/dL), trigly-
ecerides (45.5 mg/dL), total cholesterol (37.7 mg/dL), and HbA\(_1c\)
(1.6% [baseline ≥6%] and 1.9% [baseline ≥9%]).

Conclusion

Despite the cultural and environmental disadvantages present in
the Mississippi Delta, the integrated MTM treatment program
demonstrated significant health improvements across 3 chronic
diseases: hypertension, dyslipidemia, and diabetes. This model
demonstrates that a partnership between public health and phar-

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.

2 Centers for Disease Control and Prevention • www.cdc.gov/pcd/issues/2020/20_0063.htm
changes in therapy or other intervention

- Taking any appropriate actions to help improve the effectiveness of medication therapies, including initiating or modifying medication therapy via collaborative practice agreement or through recommendations to the primary provider
- Developing a medication action plan, which may include changes to medication therapy
- Delivering health education on chronic disease state and self-management practices
- Providing patient with medication adherence tools
- Initiating laboratory monitoring (including noninvasive monitoring, such as self-monitoring blood pressure or blood glucose)
- Communicating medication therapy changes and recommendations with primary provider via electronic health record or other mechanism
- Facilitating any additional referrals (eg, primary care provider, specialist providers, community health worker, social work, podiatry, optometry)

**Follow-up pharmacist MTM visit.** At the conclusion of the initial visit, the pharmacist scheduled a follow-up visit to help the patient monitor health conditions, review medication therapies, provide any additional education or counseling needed, and take appropriate actions to more effectively manage health conditions. Pertinent activities from the initial visit may occur on the follow-up visit for the pharmacist assessment, intervention, and plan. Following each visit, the pharmacist documented the encounter details in the patient’s electronic health record to share and communicate MTM recommendations with members of the clinical team and update patient action plans and medication profiles.

**Medically relevant tests.** Blood pressure was measured and evaluated at each visit with the pharmacist. If a diagnosis of diabetes was present, HbA1c levels were checked at the initial visit and then every 3 months or as deemed appropriate. A lipid panel was obtained at the initial visit and then every 3 months or as deemed appropriate.

Clinical data were collected throughout MTM implementation. Clinical parameters evaluated were SBP, DBP, LDL cholesterol, triglycerides, total cholesterol, and HbA1c. Clinical data were dependent on clinical diagnoses, specifically hypertension, dyslipidemia, diabetes, or any combination of the 3. Accordingly, HbA1c percentage was collected for patients with a diagnosis of diabetes. LDL cholesterol, triglycerides, and total cholesterol were collected for patients with dyslipidemia. SBP and DBP were collected for all patients; however, only those presenting with elevated levels were included in analyses. Furthermore, there was considerable overlap or comorbidity in patient diagnoses; therefore, totals for the reported number of participants were not mutually exclusive from those of other chronic disease conditions. Because there was no expectation of improvement for patients with clinical measures that were normal at baseline, these patients’ data for those variables were not included in the analysis.

For comparative purposes, patient data were analyzed by duration of participation in the MTM initiative. Time zero (T1), the pre-MTM intervention measure, was compared with the post-MTM intervention measure (T2). Hypertensive patients’ T2 measures were collected 6 to 12 months into participation in the MTM initiative, and T2 measures for patients with other chronic disease diagnoses were collected 9 to 12 months into program participation. Because hypertensive patients typically experienced rapid improvement after beginning the MTM intervention and had shorter participation duration, we extended their time frame for analysis. Participation duration–based analysis was needed to aggregate participants across the many years of the initiative and to facilitate the rolling admissions process, allowing a pre–post within-factor design. We used t tests to assess significance of clinical change. Accordingly, any patients with fewer than 2 clinical assessments at least 6 months apart were excluded from the study. Patients who presented with elevated clinical numbers and were enrolled in the MTM program but who had their blood pressure at goal were also excluded from hypertension analyses. For patients with multiple clinical measures in the T2 point, we used a mean of those measures.

Finally, hypertension was further analyzed by stage, broken into 4 groups according to severity of elevated blood pressures, using the higher stage of SBP or DBP at the time measurement. The Figure displays the cut-off scores used to determine normal versus elevated levels for each clinical measure, as well as a breakdown of hypertension stages used in this analysis.
Results

A total of 335 patients met the inclusion criteria for analysis. This represented a 71.3% retention rate (ie, 335 of 470 patients returned for a follow-up visit within 1 year after enrollment and were included in the comparative analysis). This population averaged 2.4 total visits per year. Grouped by diagnosis, 287 patients with hypertension, 131 patients with dyslipidemia, and 331 patients with diabetes were included in the analyses. Patients were 61.2% female and had a mean age of 60 years. The population studied was 95.0% Black, 4.5% White, and 0.5% other race.

MTM participant outcome data (Table 1) include mean baseline or pre-MTM intervention mean scores (T1) and mean post-MTM intervention scores (T2), as well as actual and relative change in each clinical measure. All clinically relevant metrics demonstrated significant improvement (\( P < .01 \); range, \(-4.2\% \) for SBP to \(-18.2\% \) for triglycerides).

Blood pressure outcomes varied considerably across disease severity or hypertension stage (Table 2). Patients with Stage III and IV hypertension (blood pressure at or above 180 systolic and/or 110 diastolic) experienced the greatest level of improvement (16.8% and 12.5%, \( P = .002 \) and \( P = .01 \), respectively). Significant results were also experienced by Stage II (\( P < .001 \)) and Stage I participants (\( P = .003 \)).

Discussion

The results of the MDHC MTM efforts strongly support the use of pharmacist-delivered MTM as a part of integrated care in rural Mississippi. MTM care delivery models have a considerable literature base to support its usefulness, although little research has targeted rural, Black populations in the Deep South (9,16–20). This program targeted a largely Black population in one of the most medically underserved areas in the United States. Despite the cultural and environmental disadvantages present in this area, the integrated MTM treatment program demonstrated significant health improvements across chronic diseases, including hypertension, dyslipidemia, and diabetes. The level of impact on clinical metrics in our study is similar to other published findings.

Pharmacists have been involved in the provision of services to ensure optimal medication use for many years. This provision has evolved from Pharmaceutical Care Services or Disease Management Services terminology in the 1990s to the consensus definition of MTM adopted by the pharmacy profession in 2004, and more recently Comprehensive Medication Management (CMM), which emphasizes the team-based approach to care. Because different terms have been used historically and the components and delivery of MTM may vary, such as with Medicare Part D MTM programs, it is important to have an understanding of the robustness of this intervention. The MDHC MTM service model incorporates the MTM core elements and aligns with the Pharmacist Patient Care Process (PPCP) (15,21). In the PPCP, the pharmacist uses a patient-centered approach in collaboration with other providers on the health care team to optimize patient health and medication outcomes. This approach is accomplished by collecting the necessary information, assessing the information collected, and analyzing the clinical effects of the patient’s therapy in the context of the patient’s overall health goals to identify and prioritize problems. The pharmacist then develops and implements an individualized, evidence-based, patient-centered care plan with other providers via collaborative practice agreement or recommendations.

This initiative used several aspects of MTM that were expected to be a good match for the needs of the Mississippi Delta, including a close working relationship between pharmacists and other care provider team members at participating clinics, following the principles of interprofessional collaborative practice, and incorporating the core elements of MTM into a robust intervention. The benefits of enhancing the team-based approach have been well docu-
mented as the quadruple aim of Interprofessional Collaborative Practice, supporting the value of close collaboration and heightened interprofessional communication on reducing the cost of care while promoting provider wellbeing and improving patient outcomes (14–18,22–26). This MTM model supports the integration of pharmacists in collaborative, team-based care models in clinic settings such as this to achieve this goal.

In our study, significant reductions were demonstrated for lipemic parameters. Serum concentrations of total cholesterol, LDL cholesterol, and triglycerides improved significantly compared with baseline. Eighty-four percent of patients with dyslipidemia also had concomitant diabetes, which is a noteworthy finding because dyslipidemia is a major risk factor for CVD in patients with diabetes (27). For patients with diabetes, significant reductions in HbA1c were demonstrated. Patients with the highest risk for diabetes complications (baseline HbA1c >9%) experienced a 1.9% reduction in HbA1c (for a 17.1% relative reduction). Similarly, SBP and DBP (analyzed separately) were significantly lower after receiving MTM services. The relative reductions observed are clinically meaningful given the various stages of hypertension at baseline. These levels of effect on clinical parameters are consistent with other published figures regarding pharmacist-delivered MTM (9,16,28–30). Improvements such as these, combined with pharmacist coaching and counseling, will likely contribute to a reduction in risk of CVD in this population.

In addition to improved patient outcomes, the design of this program provided for continuity of care with the pharmacist during primary care provider transition periods, which occurred several times in the clinic sites. The pharmacist was consistent and present to address concerns and facilitate the delivery of historical context during these transitional periods. The face-to-face encounters were helpful in patient assessment and in ensuring that patients had a good understanding of the plan. Many of these patients had complex disease states and comorbidities and this team-based approach provided efficiency for patients, while ensuring delivery of comprehensive patient care.

Limitations

This practice-based implementation initiative did not allow for a control group but was structured to evaluate patient outcomes in an actual care model. In this region with this disadvantaged population, challenges are often encountered in providing health care. Patients may be unable to attend clinic visits because of lack of transportation, primary provider transitions, and other financial barriers. Although pharmacists worked with patients to identify issues hindering care and attempted to incorporate social work and other resources, patients were not always successful in overcoming these challenges and continuing care. Pharmacists communicated effectively with collaborating providers through the FQHC electronic health record; however, their systems were not structured to capture the data necessary for the evaluation of services, requiring additional electronic documentation by the pharmacists. Through this grant-supported project, the pharmacist services provided were not billed or compensated. These identified challenges set the stage for future research to explore more options for pharmacist MTM delivery, such as through telehealth, and to explore additional payment options for team-based care.

In addition to the lack of a control group, small sample size was a limitation because it precluded the ability to conduct complex analyses to account for potential confounding factors. The intent was to describe a real-world care model and experience with a focus on the benefits of partnering with a state health department, and as such, the study was not designed as a large, randomized controlled trial. The small sample size also limited interpretation and extrapolation of our findings. Although the outcome variables improved significantly compared with baseline, a causal inference cannot be established, nor can it discount the fact that the results seen might have otherwise occurred naturally over time without the intervention. Despite this model being effective in this particular setting and population, it is uncertain whether the benefits would be seen in other disease states or in a more diverse population.

We were unable to account for the potential variability among the clinics included in the analysis. All clinics were FQHCs in the Mississippi Delta region that serviced a medically underserved sociodemographic. Inherent differences or variabilities were not captured or adjusted for in clinic characteristics during the study period. The intended study population was patients at high risk for cardiovascular complications from diabetes, hypertension, and dyslipidemia, which is typical of pharmacist-provided MTM and CMM services described in the literature and from our previous experiences. Unfortunately, this introduces the possibility of our results being biased toward positive findings, as patients with normal or well-controlled metrics were not included in the design or analyses. Regression toward the mean is expected in this scenario. The main reason for only including high-risk patients was that limited resources necessitated prioritizing patients with high disease burden, and subsequently, high risk for complications.

Another potential limitation was the variability in follow-up visits. Patient acuity and medical necessity largely determined individual follow-up scheduling. A large number of no-shows and reschedulings caused further variability among subjects regarding the number of encounters with MTM pharmacists. The analysis did not account for these varying levels of exposure to the intervention. Key differences may exist in the characteristics and disease severity between patients who had multiple versus few visits with the phar-
Pharmacists are well equipped and positioned as medication experts to contribute in a meaningful way to team-based, collaborative care. The partnership between the UMSOP and the Mississippi State Department of Health provided an opportunity to test and demonstrate the positive impact of this intervention on markers that influence CVD, in one of the most underserved and medically challenged regions of our country. This partnership demonstrates how public health and pharmacy can align to achieve the shared goals of preventing chronic disease and improving population health through implementation of innovative strategies such as the MDHC MTM model.

Acknowledgments

We thank the Aaron E. Henry Community Health Services Center, the G.A. Carmichael Family Health Center, and the Vicksburg-Warren Family Health Care Clinic where pharmacy services were provided. We are also grateful to the Mississippi State Department of Health, including Cassandra Dove, MPH; Tameka Walls, PhD; Jeffrey Jones, RPh; and Meg Pearson, PharmD, MS; as well as the Centers for Disease Control and Prevention, including Leticia Presley-Cantrell, PhD; and Aisha Penson, MEd, CHES, for their support of this project.

This work was supported by a grant from the Centers for Disease Control and Prevention through the Mississippi State Department of Health under award no. 6NU58DP00625. No copyrighted surveys, tools, or instruments were used for this research.

Author Information

Corresponding Author: Leigh Ann Ross, PharmD, BCPS, FASHP, FCCP, FAPhA, FNAP, Associate Dean for Clinical Affairs, Professor, Department of Pharmacy Practice, Director, Center for Clinical and Translational Science, Research Professor, Research Institute of Pharmaceutical Sciences, University of Mississippi School of Pharmacy, 2500 North State St, Jackson, MS 39216. Telephone: 601-984-2481. Email: laross@umc.edu.

Author Affiliations: 1University of Mississippi School of Pharmacy, Oxford, Mississippi. 2Aaron E. Henry Community Health Services Center, Clarksdale, Mississippi. 3Mississippi State Department of Health, Jackson, Mississippi. 4University of Alabama, Tuscaloosa, Alabama.

References

1. Gennuso KP, Jovaag A, Catlin BB, Rodock M, Park H. Assessment of factors contributing to health outcomes in the eight states of the Mississippi Delta Region. Prev Chronic Dis 2016;13:150440.
2. Cosby AG, Bowser DM. The health of the Delta Region: a story of increasing disparities. J Health Hum Serv Adm 2008;31(1):58–71.
3. Mississippi State Department of Health. Heart disease and stroke prevention. http://msdh.ms.gov/msdhsite/_static/43,0,297.html. Accessed August 20, 2020.
4. Sallar AM, Williams PB, Omishakin AM, Lloyd DP. Stroke prevention: awareness of risk factors for stroke among African American residents in the Mississippi delta region. J Natl Med Assoc 2010;102(2):84–94.
5. Mississippi State Department of Health. Mississippi Statistically Automated Health Resource System. http://mstahrs.msdh.ms.gov/. Accessed January 10, 2020.
6. Mikulic M. Medicine use and spending in the U.S.: total drug prescriptions dispensed in the U.S., 2009–2018. https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023. Accessed May 5, 2020.
7. Theising KM, Fritschle TL, Scholfield AM, Hicks EL, Schymik ML. Implementation and clinical outcomes of an employer-sponsored, pharmacist-provided medication therapy management program. Pharmacotherapy 2015;35(11):e159–63.
8. Tsuyuki RT, Johnson JA, Teo KK, Simpson SH, Ackman ML, Biggs RS, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002;162(10):1149–55.
9. Carter BL, Barnette DJ, Chrischilles E, Mazzotti GJ, Asali ZJ. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy 1997;17(6):1274–85.
10. Chabot I, Moisan J, Grégoire J-P, Milot A. Pharmacist intervention program for control of hypertension. Ann Pharmacother 2003;37(9):1186–93.

11. Cheema E, Sutcliffe P, Singer DRJ. The impact of interventions by pharmacists in community pharmacies on control of hypertension: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol 2014;78(6):1238–47.

12. Santschi V, Chiolero A, Colosimo AL, Platt RW, Taffé P, Burnier M, et al. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc 2014;3(2):e000718.

13. Ryan R, Santesso N, Lowe D, Hill S, Grimshaw J, Prictor M, et al. Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. Cochrane Database Syst Rev 2014;(4):CD007768.

14. Neiman AB, Ruppar T, Ho M, Garber L, Weidle PJ, Hong Y, et al. CDC Grand Rounds: improving medication adherence for chronic disease management — innovations and opportunities. MMWR Morb Mortal Wkly Rep 2018;67(17):450–5.

15. American Pharmacists Association and National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: core elements of an MTM service model, version 2.0. Washington (DC): American Pharmacists Association; 2008. https://www.pharmacist.com/sites/default/files/files/core_elements_of_an_mtm_practice.pdf. Accessed January 30, 2020.

16. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash) 2003;43(2):173–84.

17. Manganelli J. The role of clinical pharmacists in achieving clinical and quality outcomes in diabetes management. Am J Manag Care 2016;22(4 Spec No):SP128.

18. Rodis J, Sevin A, Awad MH, Porter B, Glasgow K, Fox CH, et al. Improving chronic disease outcomes through medication therapy management in federally qualified health centers. J Prim Care Community Health 2017;8(4):324–31.

19. Rodis JL, Capesius TR, Rainey JT, Awad MH, Fox CH. Pharmacists in federally qualified health centers: models of care to improve chronic disease. Prev Chronic Dis 2019;16:190163.

20. Ross LA, Bloodworth LS. Patient-centered health care using pharmacist-delivered medication therapy management in rural Mississippi. J Am Pharm Assoc (2003) 2012;52(6):802–9.

21. Joint Commission of Pharmacy Practitioners. Pharmacists’ patient care process; 2014. https://jcpp.net/wp-content/uploads/2016/03/PatientCareProcess-with-supporting-organizations.pdf. Accessed August 4, 2020.

22. Selleck CS, Fifolt M, Burkart H, Frank JS, Curry WA, Hites LS. Providing primary care using an interprofessional collaborative practice model: What clinicians have learned. J Prof Nurs 2017;33(6):410–6.

23. Zwarenstein M, Goldman J, Reeves S. Interprofessional collaboration: effects of practice-based interventions on professional practice and healthcare outcomes. Cochrane Database Syst Rev 2009;3(3):CD00072.

24. Brandt B, Lutfiyya MN, King JA, Chioreso C. A scoping review of interprofessional collaborative practice and education using the lens of the Triple Aim. J Interprof Care 2014;28(5):393–9.

25. Berwick DM, Nolan TW, Whittington J. The triple aim: care, health, and cost. Health Aff (Millwood) 2008;27(3):759–69.

26. Bodenheimer T, Sinsky C. From triple to quadruple aim: care of the patient requires care of the provider. Ann Fam Med 2014;12(6):573–6.

27. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics — 2018 update: a report from the American Heart Association. Circulation 2018;137(12):e67–492.

28. Thumar R, Zaiken K. Impact of live medication therapy management on cholesterol values in patients with cardiovascular disease. J Am Pharm Assoc (2003) 2014;54(5):526–9.

29. Fox D, Ried LD, Klein GE, Myers W, Foli K. A medication therapy management program’s impact on low-density lipoprotein cholesterol goal attainment in Medicare Part D patients with diabetes. J Am Pharm Assoc (2003) 2009;49(2):192–9.

30. Johnson M, Jastrzab R, Tate J, Johnson K, Hall-Lipsy E, Martin R, et al. Evaluation of an academic-community partnership to implement MTM services in rural communities to improve pharmaceutical care for patients with diabetes and/or hypertension. J Manag Care Spec Pharm 2018;24(2):132–41.
### Table 1. Overall MTM Clinical Laboratory Outcomes Within the First Year of Enrollment, Mississippi Delta Health Collaborative, 2009–2018

| Clinical Measure                        | No.  | Baseline Mean | Post-MTM Mean | Change   | P Value<sup>b</sup> | Relative % Change |
|-----------------------------------------|------|---------------|---------------|----------|----------------------|------------------|
| Systolic blood pressure, mm Hg          | 287  | 142.7         | 135.6         | -7.1     | <.001                | -4.2             |
| Diastolic blood pressure, mm Hg         | 191  | 89.9          | 83.6          | -6.3     | <.001                | -7.0             |
| LDL cholesterol, mg/dL                  | 112  | 140.9         | 116.0         | -24.9    | <.001                | -17.6            |
| Triglycerides, mg/dL                    | 70   | 249.9         | 204.4         | -45.5    | .001                 | -18.2            |
| Total cholesterol, mg/dL                | 82   | 245.3         | 207.6         | -37.7    | <.001                | -15.3            |
| Hemoglobin A<sub>1c</sub>, % (Baseline ≥6) | 331  | 10.7          | 9.1           | -1.6     | <.001                | -14.8            |
| Hemoglobin A<sub>1c</sub>, % (Baseline ≥9) | 275  | 11.2          | 9.3           | -1.9     | <.001                | -17.1            |

Abbreviation: LDL, low-density lipoprotein; MTM, medication therapy management.

For all patients. Normal values at baseline were excluded.

<sup>b</sup> P values determined by using paired t test.
### Table 2. Blood Pressure Change Among MTM Patients (N = 298), by Hypertension Stage, Mississippi Delta Health Collaborative, 2009–2018

| Baseline                  | No. of Patients Showing Decrease in BP, No. (%) | Change in BP Between Baseline and Follow-Up | Relative % Reduction |
|---------------------------|-----------------------------------------------|-------------------------------------------|----------------------|
|                           |                                               | BP type Baseline Mean, mm Hg | Post-MTM Mean, mm Hg | Change, mm Hg | P Value | |
| At Risk (n = 137)         | 93 (68)                                       | Systolic 128.9 | 129.0 | 0.1 | .92 | – |
|                           |                                               | Diastolic 79.3 | 77.5 | -1.8 | .03 | 2.3 |
| Stage I (n = 100)         | 77 (77)                                       | Systolic 145.1 | 139.3 | -5.7 | .003 | 3.9 |
|                           |                                               | Diastolic 84.9 | 80.9 | -4.0 | <.001 | 4.7 |
| Stage II (n = 46)         | 41 (89)                                       | Systolic 160.9 | 147.5 | -13.4 | <.001 | 8.3 |
|                           |                                               | Diastolic 92.2 | 85.1 | -7.1 | <.001 | 7.7 |
| Stage III and IV (n = 14) | 14 (100)                                      | Systolic 177.5 | 147.6 | -29.8 | .002 | 16.8 |
|                           |                                               | Diastolic 104.4 | 91.3 | -13.1 | .01 | 12.5 |

Abbreviations: —, not applicable; BP, blood pressure; MTM, medication therapy management.

* Normal values at baseline were excluded. Second laboratory result was 6 to 9 months after first visit.

* Decrease in either systolic or diastolic blood pressure.

* P values determined by using paired t test.